Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-038 in Healthy Participants and PNH Patients
NCT05876312Phase 2Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Mar 2028
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 2
01
Overview
A Phase 2 trial of agazisiran in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by ADARx Pharmaceuticals. Started Aug 2023; status: recruiting.
02
Drugs
agazisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05876312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05876312.